From GlobeNewswire: 2025-04-24 13:00:00

The sarcopenia clinical trial pipeline is robust, with 18+ key pharma companies actively developing therapeutics. No approved drug therapies exist in major markets, leading to significant unmet medical needs. Regulatory bodies are recognizing sarcopenia as a distinct condition, and early movers in this space have the potential to shape clinical guidelines.

Key takeaways from DelveInsight’s Sarcopenia Pipeline Report include 18+ active companies working on 20+ pipeline drugs. Promising therapies like BIO101, MF-300, and LPCN1148 are in various stages of clinical trials. Recent developments include platform presentations on sarcopenia treatments and FDA approvals for new drugs.

Sarcopenia is a progressive condition linked to aging, characterized by muscle loss and reduced strength. Contributing factors include chronic illness, hormonal changes, and physical inactivity. Diagnostic tools like DXA and handgrip strength assessments help identify sarcopenia, while management involves resistance training, protein intake, and emerging pharmacological therapies.

The underlying mechanisms of sarcopenia involve muscle protein turnover imbalance, mitochondrial dysfunction, and inflammatory cytokines. Anabolic hormone reduction and catabolic activity accelerate muscle breakdown, while insulin resistance and inflammation contribute to muscle loss. Standardized diagnostic frameworks and emerging therapeutic options aim to address these underlying causes.

The sarcopenia pipeline offers detailed profiles of emerging therapies segmented by stage, product type, and mechanism of action. Key companies like Biophytis and Epirium Bio are advancing pipeline drugs with unique mechanisms, such as 15-PGDH enzyme inhibitors and RNA interference. The pipeline report provides insights into the future of sarcopenia treatment and market trends.

DelveInsight’s Pharma Competitive Intelligence Service offers real-time insights on competitors and markets. Reports on sarcopenia epidemiology, market forecasts, and pipeline assessments provide comprehensive information for stakeholders in the healthcare industry. With a focus on life sciences, DelveInsight aims to support informed decision-making and strategic planning.



Read more at GlobeNewswire: Sarcopenia Clinical Trial Pipeline Appears Robust With 18+